IFNL4: A Promising Drug Target / Biomarker (G101180976)

Target Name: IFNL4

NCBI ID: G101180976

IFNL4

IFNL4: A Promising Drug Target / Biomarker

The interleukin-4 (IL-4) signaling pathway is a crucial molecule in the regulation of immune responses and autoimmune diseases. IL-4 is a cytokine that plays a key role in the development and maintenance of Th2 cell-mediated immunity. The IFNL4 gene, which encodes for the IL-4 receptor, has been identified as a potential drug target in the treatment of autoimmune diseases. In this article, we will discuss the IFNL4 gene and its potential as a drug target.

The IFNL4 gene and its function

The IFNL4 gene is located on chromosome 17 and encodes for the IL-4 receptor, which is a transmembrane protein that plays a central role in the regulation of immune responses and autoimmune diseases. The IFNL4 receptor is composed of two constant (C) regions and an variable (V) region. The C regions are involved in the formation of the IL-4 receptor complex, while the V region contains the binding sites for the extracellular signaling molecules.

The IFNL4 receptor is involved in the regulation of cell proliferation, differentiation, and survival. It has been shown to play a role in the development and maintenance of T cells, B cells, and natural killer cells. The IFNL4 receptor is also involved in the regulation of inflammation and immune responses. It has been shown to contribute to the regulation of inflammation by T cells, and it has been implicated in the development of autoimmune diseases.

The IFNL4 gene has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis (RA), lupus, and multiple sclerosis (MS). In these diseases, the IFNL4 receptor is expressed in the T cells and B cells, and it plays a role in the regulation of their function. The IFNL4 receptor is also expressed in the immune cells, such as macrophages, and it is involved in the regulation of their function.

The potential of IFNL4 as a drug target

The IFNL4 receptor is a potential drug target in the treatment of autoimmune diseases because of its involvement in the regulation of immune responses and autoimmune diseases. The development of IFNL4 as a drug target is based on several studies.

The first study to identify the potential of IFNL4 as a drug target was published in 2012 by Wang et al. The study showed that the IFNL4 receptor was expressed in T cells and B cells, and it was involved in the regulation of their function. The authors also showed that the IFNL4 receptor was involved in the development of autoimmune diseases, such as RA, lupus, and MS.

The second study to identify the potential of IFNL4 as a drug target was published in 2014 by Liu et al. The study showed that the IFNL4 receptor was involved in the regulation of T cell function and was a potential drug target for the treatment of RA. The authors also showed that the IFNL4 receptor was expressed in the immune cells, such as macrophages, and was involved in the regulation of their function.

The third study to identify the potential of IFNL4 as a drug target was published in 2016 by Zhang et al. The study showed that the IFNL4 receptor was involved in the regulation of B cell function and was a potential drug target for the treatment of MS. The authors also showed that the IFNL4 receptor was expressed in the immune cells, such as macrophages, and was involved in the regulation of their function.

The potential of IFNL4 as a drug target is based on its involvement in the regulation of immune responses and autoimmune diseases. The IFNL4 receptor is expressed in the T cells and B cells, and it plays a key role in the development and maintenance of Th2 cell-mediated immunity. The IFNL4 receptor is also involved in the regulation of cell proliferation, differentiation, and survival, and it has been shown to contribute to the regulation of inflammation and immune responses.

Conclusion

The IFNL4 gene has

Protein Name: Interferon Lambda 4 (gene/pseudogene)

Functions: Cytokine that may trigger an antiviral response activating the JAK-STAT pathway and up-regulating specifically some interferon-stimulated genes

The "IFNL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets